AL001 (latozinemab)
Frontotemporal Dementia with progranulin mutation (FTD-GRN)
Phase 3Active - INFRONT-3 trial enrolled
Key Facts
Indication
Frontotemporal Dementia with progranulin mutation (FTD-GRN)
Phase
Phase 3
Status
Active - INFRONT-3 trial enrolled
Company
About Alector
Alector is a clinical-stage biotech company with a mission to conquer neurodegenerative diseases by modulating the immune system. Its strategy is validated by major partnerships with GSK and AbbVie, and it is advancing a late-stage pipeline led by latozinemab in Phase 3 for frontotemporal dementia. The company's proprietary Alector Brain Carrier (ABC) platform aims to solve the critical challenge of blood-brain barrier delivery, positioning it at the forefront of a novel therapeutic paradigm.
View full company profile